Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has announced that Tekturna HCT tablets have been approved by the FDA as a single-tablet combination of two high blood pressure medicines - Tekturna and the diuretic hydrochlorothiazide.
Subscribe to our email newsletter
The two medicines in this single-tablet combination work together to lower blood pressure, with clinical data showing that the combination of Tekturna and hydrochlorothiazide (HCTZ) offers greater blood pressure reductions than either component alone. This is claimed to be the first regulatory approval of a single-tablet combination therapy involving Tekturna, known as Rasilez outside the US. Tekturna HCT is approved for patients not controlled by either medicine alone but should not be used before other medications have been tried first, Novartis said.
Marjorie Gatlin, vice president, cardiovascular and metabolic therapeutic area head, US medical, Novartis, said: “Most patients need at least two medicines to control their high blood pressure. Novartis is very proud to introduce this innovative combination. Tekturna HCT incorporates the latest direct renin inhibition technology and offers an important new option for patients who need greater blood pressure control.”